Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
90 hedge funds and large institutions have $115M invested in Antares Pharma, Inc. in 2015 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 29 reducing their positions, and 8 closing their positions.
1,163% more call options, than puts
Call options by funds: $505K | Put options by funds: $40K
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
17% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 29
2% more funds holding
Funds holding: 88 → 90 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less capital invested
Capital invested by funds: $145M → $115M (-$29.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.72M |
| 2 |
BC
Broadfin Capital
New York
|
+$1.76M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.42M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$838K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$614K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$5.76M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.49M |
| 3 |
JP Morgan Chase
New York
|
-$1.76M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.57M |
| 5 |
Morgan Stanley
New York
|
-$644K |
ATRS Hedge Fund Activity: Q3 2015 in Review
90 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2015, worth a combined $115M — down 20% from $145M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ATRS positions and 8 closed out — a net gain of 2 holders — while 34 added to existing stakes and 29 trimmed.
The largest buyer was Armistice Capital, adding an estimated $3.72M. The largest seller was Deerfield Management, cutting an estimated $5.76M.
- 90 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2015, up from 88 in Q2 2015.
- Funds reported $115M of Antares Pharma, Inc. stock for Q3 2015, down 20% quarter-over-quarter.
- 10 funds opened new Antares Pharma, Inc. positions in Q3 2015 and 8 closed out, a net change of +2 holders.
- The largest Antares Pharma, Inc. buyer in Q3 2015 was Armistice Capital, an estimated $3.72M added.
- The largest Antares Pharma, Inc. seller in Q3 2015 was Deerfield Management, an estimated $5.76M sold.
Based on aggregated 13F filings for Q3 2015.